IJBAF, May, 2025, 13(5): 37-44

ISSN: 2320 – 0774

International Journal of Biotechnology and Allied Fields (IJBAF)

www.ijbaf.com

'Connecting Researchers...'

STUDY OF GENETIC ENGINEERING AND GENE EDITING

KHAN JA

Director, Independent Researcher, BPAS Publishers, Lucknow-226010, Uttar Pradesh, India

***Corresponding Author: Dr. Jahir Alam Khan: E Mail: directorbpa1@gmail.com**

Received 8th Aug. 2024; Revised 5th Sept. 2024; Accepted 8th Oct. 2024; Available online 1st May 2025

ABSTRACT

Genetic engineering and gene editing represent some of the most transformative advances in modern biology and biotechnology. These technologies enable precise modification of DNA to alter traits, cure diseases, and create new biological applications in agriculture, medicine, and industry. Over the past four decades, techniques such as recombinant DNA technology, transgenesis, and genome editing have developed from experimental concepts to widely applied tools. Recently, gene editing tools such as CRISPR-Cas systems, TALENs, and zinc finger nucleases (ZFNs) have revolutionized the field due to their precision, efficiency, and accessibility. Their applications range from genetically modified crops to gene therapy in humans, and from industrial biotechnology to synthetic biology. However, ethical, regulatory, and biosafety challenges remain critical concerns, especially in the context of human germline modification and ecological impacts. This review provides a comprehensive overview of the fundamentals of genetic engineering and gene editing, their applications across sectors, the ethical and regulatory frameworks that govern them, and future perspectives for safe and responsible utilization.

Keywords: Genetic engineering; Gene editing; CRISPR-Cas9; TALENs; Zinc Finger Nucleases; Recombinant DNA; Biotechnology; Ethics; Regulation; Genome editing

1. INTRODUCTION

The discovery of the structure of DNA in 1953 and the subsequent development of molecular biology techniques laid the foundation for genetic engineering **[1]**. Genetic engineering broadly refers to the deliberate modification of an organism's genetic material using biotechnology. This has enabled scientists to manipulate genes to enhance crop yield, develop therapeutic proteins, and create genetically modified organisms (GMOs) **[2-6]**.

In recent years, the emergence of genome editing tools has taken this field to an unprecedented level of precision and control. Unlike conventional genetic engineering, which often relied on random insertion of foreign DNA, gene editing technologies allow scientists to make targeted changes at specific genomic sites. These advancements have profound implications for medicine, agriculture, industry, and environmental sustainability **[7-15]**.

2. Historical Background of Genetic Engineering [16-25]

- **1970s:** Recombinant DNA technology pioneered by Cohen and Boyer, leading to the first genetically engineered bacteria.
- **1980s:** First transgenic plants and animals created.
- **1990:** First gene therapy trial in humans.
- **2000s:** Human Genome Project completed, providing a blueprint for editing.
- **2012 onwards:** CRISPR-Cas9 emerges as the most powerful gene editing tool.

Table 1 (below) summarizes key milestones.

Table 1: Key Historical Milestones in Genetic Engineering

Year	Discovery / Advancement	Impact
1973	Recombinant DNA by Cohen & Boyer	Foundation of genetic engineering
1983	First transgenic plant	Start of GM agriculture
1990	First gene therapy in humans	Clinical applications begin
2000	Human Genome Project completed	Blueprint for gene editing
2012	CRISPR-Cas9 developed	Revolutionized gene editing

3. Fundamentals of Gene Editing

Gene editing relies on engineered nucleases that introduce double-strand breaks (DSBs) at targeted sites. The cell then repairs these breaks via **non-homologous end joining (NHEJ)** or **homology-directed repair (HDR)**.

- **ZFNs (Zinc Finger Nucleases):** Early tools, highly specific but technically complex.
- **TALENs (Transcription Activator-Like Effector Nucleases):** Easier to design than ZFNs, but still labor-intensive.
- **CRISPR-Cas9:** Uses a guide RNA to target specific DNA sequences, making it inexpensive, efficient, and versatile.
- **Meganucleases:** Rare-cutting endonucleases with natural sequence specificity.



Figure 1: Basic mechanism of CRISPR-Cas9 gene editing

4. Applications of Genetic Engineering and Gene Editing

4.1 Agriculture

- Development of **GM crops** (Bt cotton, golden rice).
- Gene editing for **drought tolerance, pest resistance, enhanced nutrition**.
- Potential for reducing chemical pesticide and fertilizer use.

4.2 Medicine

- **Gene therapy** for genetic diseases (sickle cell anemia, hemophilia).
- **Cancer immunotherapy** (CAR-T cells).
- Development of **vaccines** (e.g., mRNA COVID-19 vaccines relied on genetic engineering).
- Regenerative medicine (stem cells, organoids).

4.3 Industry

- Genetically engineered microbes for **biofuels, bioplastics, industrial enzymes**.
- Pharmaceutical production (insulin, monoclonal antibodies).

Table 2: Applications of Genetic Engineering in Different Sectors

Sector	Application	Example
Agriculture	Pest-resistant crops	Bt Cotton
Agriculture	Nutritionally enriched food	Golden Rice
Medicine	Gene therapy	Sickle cell anemia trials
Medicine	Immunotherapy	CAR-T cell therapy
Industry	Enzyme production	Amylase for detergents
Industry	Biofuels	Algal biofuel production

Table 3: Applications of genetic engineering across agriculture, medicine, and industry

Agriculture	Medicine	Industry
Bt Cotton (insect resistance)	Gene therapy for hemophilia	Recombinant insulin production
Golden Rice (Vitamin A)	CAR-T cell therapy (cancer)	Enzyme production (amylase, cellulase)
Drought-tolerant maize	Recombinant vaccines (Hepatitis B, COVID-19)	Biofuels (ethanol, biodiesel)
Nutrient enrichment (biofortification)	Stem cell engineering	Bioremediation (oil spill bacteria)

5. Ethical, Legal and Social Issues (ELSI)

- **Human germline editing:** Risk of creating "designer babies".
- **Ecological impact:** GM crops potentially affecting biodiversity.
- **Equity concerns:** High costs limit access to therapies in developing nations.
- **Dual-use concerns:** Potential misuse for bioterrorism.

6. Regulatory and Policy Framework

- **India:** Genetic Engineering Appraisal Committee (GEAC), Department of Biotechnology (DBT), ICMR guidelines.
- **Global:** WHO and UNESCO call for moratoriums on human germline editing.
- **USA & EU:** FDA, NIH, EFSA provide regulatory oversight.

Table 4: International Regulations on Gene Editing

Region	Key Regulatory Body	Focus
India	GEAC, DBT, ICMR	GM crops, clinical trials
USA	FDA, NIH	Gene therapy approval
EU	EFSA	GM crops and food safety
Global	WHO, UNESCO	Ethical frameworks

7. Challenges and Limitations

- Off-target effects of CRISPR.
- Ethical debates on germline editing.
- Public mistrust of GMOs.
- Regulatory uncertainty across countries.

8. Future Prospects

- **Precision medicine** tailored to individual genomes.
- **Synthetic biology** combining gene editing with artificial life forms.
- **Next-generation tools**: base editors and prime editors.
- Potential to address global food security and climate change challenges.

Graph showing global research publications in gene editing (PubMed 2000–2025) **(Figure 2)**.



Figure 2: Growth of global gene editing publications (2000–2025)

9. CONCLUSION

Genetic engineering and gene editing have fundamentally transformed life sciences, offering solutions in healthcare, agriculture, and industry. With CRISPR and other emerging tools, the potential to cure genetic diseases, enhance crop resilience, and create sustainable bio-industries is closer to reality than ever before. However, ethical concerns, biosafety, and global regulatory harmonization remain vital challenges. For India and the world, the responsible adoption of these technologies can shape a healthier and more sustainable future.

REFERENCES

[1] Jinek M, *et al*. A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. *Science*. 2012;337(6096):816–821.

[2] Doudna JA, Charpentier E. Genome editing: The new frontier of genome engineering with CRISPR-Cas9. *Nature*. 2014; 505(7485): 629–636.

[3] Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. *Trends Biotechnol*. 2013;31(7):397–405.

[4] Porteus MH. A new class of medicines through DNA editing. *N Engl J Med*. 2019;380:947–959.

[5] National Human Genome Research Institute. A brief history of genetic engineering. [Online].

[6] WHO. Human genome editing: Report of the WHO Expert Advisory Committee. 2021.

[7] Indian Council of Medical Research (ICMR). National guidelines for gene therapy product development. 2019.

[8] GEAC (India). Biosafety regulations for genetically engineered organisms. 2020.

[9] Zhang F, *et al*. CRISPR technology: Applications in human disease. *Cell*. 2021;184:278–293.

[10] Gupta PK, *et al*. Genetic engineering in Indian agriculture. *Curr Sci*. 2018;115(6):1035–1045.

[11] Barrangou R, Doudna JA. Applications of CRISPR technologies in research and beyond. *Nat Biotechnol.* 2016;34(9):933–941.

[12] Cox DBT, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. *Nat Med.* 2015;21(2):121–131.

[13] Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature.* 2016;533(7603):420–424.

[14] Anzalone AV, *et al*. Search-and-replace genome editing without double-strand breaks or donor DNA. *Nature.* 2019;576(7785):149–157.

[15] Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. *Nat Rev Mol Cell Biol.* 2013;14(1):49–55.

[16] Carroll D. Genome engineering with zinc-finger nucleases. *Genetica.* 2011;138(5):463–468.

[17] Porteus MH. A new class of medicines through DNA editing. *N Engl J Med.* 2019;380(10):947–959.

[18] WHO Expert Advisory Committee on Human Genome Editing. *Human Genome Editing: Recommendations.* Geneva: World Health Organization; 2021. PubMed

[19] ICMR–DBT. *National Guidelines for Gene Therapy Product Development & Clinical Trials.* New Delhi: Indian Council of Medical Research; 2019.

[20] GEAC (MoEFCC, Govt. of India). *Guidelines and SOPs for Environmental Risk Assessment of Genetically Engineered Plants.* 2020.

[21] EFSA Panel on GMO. Guidance on the environmental risk assessment of GM plants. *EFSA J.* 2010;8(11):1879 (and updates).

[22] FDA. *Human Gene Therapy for Rare Diseases – Guidance for Industry.* Silver Spring, MD: Food & Drug Administration; 2020.

[23] ISAAA. *Global Status of Commercialized Biotech/GM Crops: 2019 (Brief 55).* 2020. ISAAA+2ISAAA+2

[24] Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: an update. *J Gene Med.* 2018;20(5):e3015. Wiley Online Library

[25] Edelstein ML, Abedi MR, Wixon J, Edelstein RM. Gene therapy clinical trials worldwide to 2023—an update. *J Gene Med.* 2023;25(5):e3510. (March 2023 update: ~3,900 trials in 46 countries.) PubMedWiley Online Library